CM336 Plus Isatuximab for Newly Diagnosed Multiple Myeloma With Renal Impairment

Summary

This study is a single-center, single-arm, open-label, Phase II interventional clinical trial designed to evaluate the efficacy and safety of a CM336 and isatuximab regimen in patients with newly diagnosed multiple myeloma (NDMM) accompanied by renal impairment (\[eGFR\] \< 40 mL/min). Enrolled subjects will receive three consecutive cycles of induction therapy with CM336 in combination with isatuximab.

Timeline

Start

2026-07-25

Primary completion

2028-05-01

Completion

2028-12-30

Drugs

Indications